{"groups":[{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG000","title":"Part A Cohort A1"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG001","title":"Part A Cohort A-1"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG002","title":"Part B Cohort B1"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG003","title":"Part B Cohort B2"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG004","title":"Part B Cohort B3"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG005","title":"Part B Cohort B5"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n* Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle.\n* Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"FG006","title":"Part C Cohort C1"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}],"type":"Discontinued study treatment, but follow-up visit was not completed due to primary study condition"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}],"type":"Withdrawal by Parent/Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"1"}],"type":"Received At Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"0"}],"comment":"A participant was identified as having completed the study if the participant died while on the study or the participant discontinued study treatment and completed the follow-up period at the time of the final analysis.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}